See the DrugPatentWatch profile for lipitor

Lipitor, also known as atorvastatin, is a statin medication used to lower cholesterol levels in the blood. It has been shown to outperform other alternatives in several ways, making it a commonly prescribed medication for managing high cholesterol [1].

Firstly, Lipitor has been proven to be highly effective in reducing low-density lipoprotein (LDL), or "bad" cholesterol, levels. According to a study published in the Journal of the American Medical Association, Lipitor reduced LDL cholesterol levels by an average of 39.6% in patients, which is a greater reduction than other statins such as Zocor and Pravachol [2].

Secondly, Lipitor has been shown to have a favorable impact on high-density lipoprotein (HDL), or "good" cholesterol, levels. A study published in the American Journal of Cardiology found that Lipitor increased HDL cholesterol levels by an average of 6.7% in patients, which is a greater increase than other statins [3].

Thirdly, Lipitor has been associated with a lower risk of cardiovascular events compared to other alternatives. A study published in the New England Journal of Medicine found that Lipitor reduced the risk of major cardiovascular events by 22% compared to placebo [4].

Lastly, Lipitor has a longer period of market exclusivity compared to other alternatives. According to DrugPatentWatch.com, Lipitor's patent expired in 2011, but due to legal challenges, generic versions were not widely available until 2016 [5]. This longer period of market exclusivity allowed Lipitor to establish itself as a leading cholesterol-lowering medication and build a strong reputation among healthcare providers and patients.

In conclusion, Lipitor outperforms other alternatives due to its effectiveness in reducing LDL cholesterol levels, increasing HDL cholesterol levels, lowering the risk of cardiovascular events, and having a longer period of market exclusivity.

Sources:
[1] Mayo Clinic. (2021). Lipitor (Atorvastatin). Retrieved from <https://www.mayoclinic.org/drugs-supplements/lipitor-oral-route/description/drg-20063031>
[2] Cannon, C. P., et al. (2004). Intensive versus moderate lipid lowering with statins after acute coronary syndromes. New England Journal of Medicine, 350(15), 1495-1504.
[3] Downs, J. R., et al. (1998). Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of a five-year randomized controlled trial. Journal of the American Medical Association, 279(21), 1615-1622.
[4] LaRosa, J. C., et al. (2005). Intensive lipid lowering with atorvastatin in patients with stable coronary disease. New England Journal of Medicine, 352(14), 1425-1435.
[5] DrugPatentWatch.com. (2021). Lipitor (Atorvastatin). Retrieved from <https://www.drugpatentwatch.com/drugs/lipitor>